Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.

Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, Bovi JA, Robinson C, Konski A, Khuntia D, Grosshans D, Benzinger TLS, Bruner D, Gilbert MR, Roberge D, Kundapur V, Devisetty K, Shah S, Usuki K, Anderson BM, Stea B, Yoon H, Li J, Laack NN, Kruser TJ, Chmura SJ, Shi W, Deshmukh S, Mehta MP, Kachnic LA; for NRG Oncology.

J Clin Oncol. 2020 Feb 14:JCO1902767. doi: 10.1200/JCO.19.02767. [Epub ahead of print]

PMID:
32058845
2.

Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN).

Aschenbrenner AJ, James BD, McDade E, Wang G, Lim YY, Benzinger TLS, Cruchaga C, Goate A, Xiong C, Perrin R, Buckles V, Allegri R, Berman SB, Chhatwal JP, Fagan A, Farlow M, O'Connor A, Ghetti B, Graff-Radford N, Goldman J, Gräber S, Karch CM, Lee JH, Levin J, Martins RN, Masters C, Mori H, Noble J, Salloway S, Schofield P, Morris JC, Bateman RJ, Hassenstab J; Dominantly Inherited Alzheimer Network.

Alzheimers Dement. 2020 Jan;16(1):219-228. doi: 10.1002/alz.12010.

PMID:
31914221
3.

Functional connectivity among brain regions affected in Alzheimer's disease is associated with CSF TNF-α in APOE4 carriers.

Contreras JA, Aslanyan V, Sweeney MD, Sanders LMJ, Sagare AP, Zlokovic BV, Toga AW, Han SD, Morris JC, Fagan A, Massoumzadeh P, Benzinger TL, Pa J.

Neurobiol Aging. 2020 Feb;86:112-122. doi: 10.1016/j.neurobiolaging.2019.10.013. Epub 2019 Nov 5.

4.

Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease.

Llibre-Guerra JJ, Li Y, Schindler SE, Gordon BA, Fagan AM, Morris JC, Benzinger TLS, Hassenstab J, Wang G, Allegri R, Berman SB, Chhatwal J, Farlow MR, Holtzman DM, Jucker M, Levin J, Noble JM, Salloway S, Schofield P, Karch C, Fox NC, Xiong C, Bateman RJ, McDade E.

JAMA Netw Open. 2019 Dec 2;2(12):e1917126. doi: 10.1001/jamanetworkopen.2019.17126.

5.

The Relation Between Personality and Biomarkers in Sensitivity and Conversion to Alzheimer-Type Dementia.

Duchek JM, Aschenbrenner AJ, Fagan AM, Benzinger TLS, Morris JC, Balota DA.

J Int Neuropsychol Soc. 2019 Dec 11:1-11. doi: 10.1017/S1355617719001358. [Epub ahead of print]

PMID:
31822309
6.

Overview of MR Imaging Volumetric Quantification in Neurocognitive Disorders.

Raji CA, Ly M, Benzinger TLS.

Top Magn Reson Imaging. 2019 Dec;28(6):311-315. doi: 10.1097/RMR.0000000000000224.

PMID:
31794503
7.

Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Yang P, Perlmutter JS, Benzinger TLS, Morris JC, Xu J.

Ageing Res Rev. 2020 Jan;57:100994. doi: 10.1016/j.arr.2019.100994. Epub 2019 Nov 22. Review.

8.

What are the threats to successful brain and cognitive aging?

Gallagher M, Okonkwo OC, Resnick SM, Jagust WJ, Benzinger TLS, Rapp PR.

Neurobiol Aging. 2019 Nov;83:130-134. doi: 10.1016/j.neurobiolaging.2019.04.016.

PMID:
31732016
9.

Heterogeneity Diffusion Imaging of gliomas: Initial experience and validation.

Wang Q, Pérez-Carrillo GJG, Ponisio MR, LaMontagne P, Dahiya S, Marcus DS, Milchenko M, Shimony J, Liu J, Chen G, Salter A, Massoumzadeh P, Miller-Thomas MM, Rich KM, McConathy J, Benzinger TLS, Wang Y.

PLoS One. 2019 Nov 14;14(11):e0225093. doi: 10.1371/journal.pone.0225093. eCollection 2019.

10.

Differences in Driving Outcomes Among Cognitively Normal African American and Caucasian Older Adults.

Babulal GM, Stout SH, Williams MM, Rajasekar G, Harmon A, Vivoda J, Zuelsdorff M, Benzinger TLS, Morris JC, Ances B, Roe CM.

J Racial Ethn Health Disparities. 2019 Nov 4. doi: 10.1007/s40615-019-00655-z. [Epub ahead of print]

PMID:
31686371
11.

The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases.

Li H, Yang P, Knight W, Guo Y, Perlmutter JS, Benzinger TLS, Morris JC, Xu J.

J Neurochem. 2020 Jan;152(2):235-251. doi: 10.1111/jnc.14898. Epub 2019 Nov 4.

12.

Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease.

Wang G, Aschenbrenner AJ, Li Y, McDade E, Liu L, Benzinger TLS, Bateman RJ, Morris JC, Hassenstab JJ, Xiong C.

Alzheimers Dement (N Y). 2019 Sep 5;5:450-457. doi: 10.1016/j.trci.2019.07.007. eCollection 2019.

13.

Association between personality and tau-PET binding in cognitively normal older adults.

Schultz SA, Gordon BA, Mishra S, Su Y, Morris JC, Ances BM, Duchek JM, Balota DA, Benzinger TLS.

Brain Imaging Behav. 2019 Sep 5. doi: 10.1007/s11682-019-00163-y. [Epub ahead of print]

PMID:
31486975
14.

Sex modulates the ApoE ε4 effect on brain tau deposition measured by 18F-AV-1451 PET in individuals with mild cognitive impairment.

Liu M, Paranjpe MD, Zhou X, Duy PQ, Goyal MS, Benzinger TLS, Lu J, Wang R, Zhou Y.

Theranostics. 2019 Jul 9;9(17):4959-4970. doi: 10.7150/thno.35366. eCollection 2019.

15.

Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains.

Xu J, Sun J, Perrin RJ, Mach RH, Bales KR, Morris JC, Benzinger TLS, Holtzman DM.

Ann Clin Transl Neurol. 2019 Aug;6(8):1423-1434. doi: 10.1002/acn3.50837. Epub 2019 Jul 9.

16.

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.

Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, Fagan AM, Bateman RJ.

Neurology. 2019 Oct 22;93(17):e1647-e1659. doi: 10.1212/WNL.0000000000008081. Epub 2019 Aug 1.

PMID:
31371569
17.

Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers.

Schultz AP, Kloet RW, Sohrabi HR, van der Weerd L, van Rooden S, Wermer MJH, Moursel LG, Yaqub M, van Berckel BNM, Chatterjee P, Gardener SL, Taddei K, Fagan AM, Benzinger TL, Morris JC, Sperling R, Johnson K, Bateman RJ; Dominantly Inherited Alzheimer Network, Gurol ME, van Buchem MA, Martins R, Chhatwal JP, Greenberg SM.

Ann Neurol. 2019 Oct;86(4):616-625. doi: 10.1002/ana.25560. Epub 2019 Aug 12.

PMID:
31361916
18.

Neuroinflammation and Myelin Status in Alzheimer's Disease, Parkinson's Disease, and Normal Aging Brains: A Small Sample Study.

Han F, Perrin RJ, Wang Q, Wang Y, Perlmutter JS, Morris JC, Benzinger TLS, Xu J.

Parkinsons Dis. 2019 Jul 4;2019:7975407. doi: 10.1155/2019/7975407. eCollection 2019.

19.

Automated production of a sphingosine-1 phosphate receptor 1 (S1P1) PET radiopharmaceutical [11C]CS1P1 for human use.

Luo Z, Gu J, Dennett RC, Gaehle GG, Perlmutter JS, Chen DL, Benzinger TLS, Tu Z.

Appl Radiat Isot. 2019 Oct;152:30-36. doi: 10.1016/j.apradiso.2019.06.029. Epub 2019 Jun 20.

PMID:
31280104
20.

Acute Rodent Tolerability, Toxicity, and Radiation Dosimetry Estimates of the S1P1-Specific Radioligand [11C]CS1P1.

Liu H, Laforest R, Gu J, Luo Z, Jones LA, Gropler RJ, Benzinger TLS, Tu Z.

Mol Imaging Biol. 2019 Jun 4. doi: 10.1007/s11307-019-01380-z. [Epub ahead of print]

PMID:
31165387
21.

Higher Body Mass Index Is Associated with Lower Cortical Amyloid-β Burden in Cognitively Normal Individuals in Late-Life.

Thirunavu V, McCullough A, Su Y, Flores S, Dincer A, Morris JC, Cruchaga C, Benzinger TLS, Gordon BA.

J Alzheimers Dis. 2019;69(3):817-827. doi: 10.3233/JAD-190154.

PMID:
31156169
22.

The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study.

Paranjpe MD, Chen X, Liu M, Paranjpe I, Leal JP, Wang R, Pomper MG, Wong DF, Benzinger TLS, Zhou Y; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2019;22:101795. doi: 10.1016/j.nicl.2019.101795. Epub 2019 Mar 28.

23.

A 2.5-Year Longitudinal Assessment of Naturalistic Driving in Preclinical Alzheimer's Disease.

Roe CM, Stout SH, Rajasekar G, Ances BM, Jones JM, Head D, Benzinger TLS, Williams MM, Davis JD, Ott BR, Warren DK, Babulal GM.

J Alzheimers Dis. 2019;68(4):1625-1633. doi: 10.3233/JAD-181242.

24.

MRI safety risks in the obese: The case of the disposable lighter stored in the pannus.

Gach HM, Mackey SL, Hausman SE, Jackson DR, Benzinger TL, Henke L, Murphy LA, Fluchel JL, Cai B, Zoberi JE, Garcia-Ramirez J, Mutic S, Schwarz JK.

Radiol Case Rep. 2019 Mar 15;14(5):634-638. doi: 10.1016/j.radcr.2019.02.023. eCollection 2019 May.

25.

Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease.

Wang Q, Wang Y, Liu J, Sutphen CL, Cruchaga C, Blazey T, Gordon BA, Su Y, Chen C, Shimony JS, Ances BM, Cairns NJ, Fagan AM, Morris JC, Benzinger TLS.

Neuroimage Clin. 2019;22:101767. doi: 10.1016/j.nicl.2019.101767. Epub 2019 Mar 13.

26.

Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease.

Vöglein J, Paumier K, Jucker M, Preische O, McDade E, Hassenstab J, Benzinger TL, Noble JM, Berman SB, Graff-Radford NR, Ghetti B, Farlow MR, Chhatwal J, Salloway S, Xiong C, Karch CM, Cairns N, Mori H, Schofield PR, Masters CL, Goate A, Buckles V, Fox N, Rossor M, Chrem P, Allegri R, Ringman JM, Höglinger G, Steiner H, Dieterich M, Haass C, Laske C, Morris JC, Bateman RJ, Danek A, Levin J; Dominantly Inherited Alzheimer Network.

Brain. 2019 May 1;142(5):1429-1440. doi: 10.1093/brain/awz050.

PMID:
30897203
27.

Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies.

Su Y, Flores S, Wang G, Hornbeck RC, Speidel B, Joseph-Mathurin N, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Jack CR Jr, Farlow MR, Salloway S, Snider BJ, Berman SB, Roberson ED, Brosch J, Jimenez-Velazques I, van Dyck CH, Galasko D, Yuan SH, Jayadev S, Honig LS, Gauthier S, Hsiung GR, Masellis M, Brooks WS, Fulham M, Clarnette R, Masters CL, Wallon D, Hannequin D, Dubois B, Pariente J, Sanchez-Valle R, Mummery C, Ringman JM, Bottlaender M, Klein G, Milosavljevic-Ristic S, McDade E, Xiong C, Morris JC, Bateman RJ, Benzinger TLS.

Alzheimers Dement (Amst). 2019 Feb 22;11:180-190. doi: 10.1016/j.dadm.2018.12.008. eCollection 2019 Dec.

28.

Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease.

Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, Wang G, Graham DL, Shaw LM, Trojanowski JQ, Hassenstab JJ, Benzinger TLS, Cruchaga C, Jucker M, Levin J, Chhatwal JP, Noble JM, Ringman JM, Graff-Radford NR, Holtzman DM, Ladenson JH, Morris JC, Bateman RJ, Xiong C, Fagan AM; Dominantly Inherited Alzheimer Network.

Alzheimers Dement. 2019 May;15(5):655-665. doi: 10.1016/j.jalz.2018.12.019. Epub 2019 Mar 4.

PMID:
30846386
29.

Tau positron emission tomography imaging in C9orf72 repeat expansion carriers.

Ly CV, Koenig L, Christensen J, Gordon B, Beaumont H, Dahiya S, Chen J, Su Y, Nelson B, Jockel-Balsarotti J, Drain C, Jerome G, Morris JC, Fagan AM, Harms MB, Benzinger TLS, Miller TM, Ances BM.

Eur J Neurol. 2019 Sep;26(9):1235-1239. doi: 10.1111/ene.13940. Epub 2019 Mar 25.

PMID:
30790403
30.

Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onset.

Wang G, Coble D, McDade EM, Hassenstab J, Fagan AM, Benzinger TLS, Bateman RJ, Morris JC, Xiong C; Dominantly Inherited Alzheimer Network (DIAN).

Alzheimers Dement. 2019 Apr;15(4):506-514. doi: 10.1016/j.jalz.2018.12.008. Epub 2019 Feb 15.

PMID:
30773445
31.

Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.

Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, Chen C, Su Y, McDade EM, Wang G, Li Y, Hassenstab J, Aschenbrenner A, Hornbeck R, Jack CR, Ances BM, Berman SB, Brosch JR, Galasko D, Gauthier S, Lah JJ, Masellis M, van Dyck CH, Mintun MA, Klein G, Ristic S, Cairns NJ, Marcus DS, Xiong C, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS.

Brain. 2019 Apr 1;142(4):1063-1076. doi: 10.1093/brain/awz019.

PMID:
30753379
32.

Structural signature of sporadic Creutzfeldt-Jakob disease.

Navid J, Day GS, Strain J, Perrin RJ, Bucelli RC, Dincer A, Wisch JK, Soleimani-Meigooni D, Morris JC, Benzinger TLS, Ances BM.

Eur J Neurol. 2019 Aug;26(8):1037-1043. doi: 10.1111/ene.13930. Epub 2019 Mar 25.

PMID:
30735286
33.

Persistent metabolic youth in the aging female brain.

Goyal MS, Blazey TM, Su Y, Couture LE, Durbin TJ, Bateman RJ, Benzinger TL, Morris JC, Raichle ME, Vlassenko AG.

Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):3251-3255. doi: 10.1073/pnas.1815917116. Epub 2019 Feb 4. Erratum in: Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5198.

34.

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease.

Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Gräber S, Kuder-Buletta E, LaFougere C, Laske C, Vöglein J, Levin J, Masters CL, Martins R, Schofield PR, Rossor MN, Graff-Radford NR, Salloway S, Ghetti B, Ringman JM, Noble JM, Chhatwal J, Goate AM, Benzinger TLS, Morris JC, Bateman RJ, Wang G, Fagan AM, McDade EM, Gordon BA, Jucker M; Dominantly Inherited Alzheimer Network.

Nat Med. 2019 Feb;25(2):277-283. doi: 10.1038/s41591-018-0304-3. Epub 2019 Jan 21.

35.

Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction.

Nation DA, Sweeney MD, Montagne A, Sagare AP, D'Orazio LM, Pachicano M, Sepehrband F, Nelson AR, Buennagel DP, Harrington MG, Benzinger TLS, Fagan AM, Ringman JM, Schneider LS, Morris JC, Chui HC, Law M, Toga AW, Zlokovic BV.

Nat Med. 2019 Feb;25(2):270-276. doi: 10.1038/s41591-018-0297-y. Epub 2019 Jan 14.

36.

Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease.

Lucey BP, McCullough A, Landsness EC, Toedebusch CD, McLeland JS, Zaza AM, Fagan AM, McCue L, Xiong C, Morris JC, Benzinger TLS, Holtzman DM.

Sci Transl Med. 2019 Jan 9;11(474). pii: eaau6550. doi: 10.1126/scitranslmed.aau6550. Erratum in: Sci Transl Med. 2020 Jan 8;12(525):.

37.

Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.

Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS, Cruchaga C, Fagan AM, Grant E, Gordon BA, Holtzman DM, Xiong C.

JAMA Neurol. 2019 Mar 1;76(3):264-273. doi: 10.1001/jamaneurol.2018.4249.

38.

Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease.

Wang G, Xiong C, McDade EM, Hassenstab J, Aschenbrenner AJ, Fagan AM, Benzinger TLS, Gordon BA, Morris JC, Li Y, Bateman RJ; Dominantly Inherited Alzheimer Network (DIAN).

Alzheimers Dement (N Y). 2018 Dec 7;4:669-676. doi: 10.1016/j.trci.2018.10.009. eCollection 2018.

39.

Tau Positron Emission Tomography Binding Is Not Elevated in HIV-Infected Individuals.

Cooley SA, Strain JF, Beaumont H, Boerwinkle AH, Doyle J, Morris JC, Benzinger TL, Ances BM.

J Infect Dis. 2019 Jun 5;220(1):68-72. doi: 10.1093/infdis/jiy663.

PMID:
30561665
40.

Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network.

Bussy A, Snider BJ, Coble D, Xiong C, Fagan AM, Cruchaga C, Benzinger TLS, Gordon BA, Hassenstab J, Bateman RJ, Morris JC; Dominantly Inherited Alzheimer Network.

Neurobiol Aging. 2019 Mar;75:42-50. doi: 10.1016/j.neurobiolaging.2018.10.011. Epub 2018 Oct 13.

PMID:
30530186
41.

The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.

Twohig D, Rodriguez-Vieitez E, Sando SB, Berge G, Lauridsen C, Møller I, Grøntvedt GR, Bråthen G, Patra K, Bu G, Benzinger TLS, Karch CM, Fagan A, Morris JC, Bateman RJ, Nordberg A, White LR, Nielsen HM; Dominantly Inherited Alzheimer Network (DIAN).

Acta Neuropathol Commun. 2018 Nov 26;6(1):130. doi: 10.1186/s40478-018-0624-z.

42.

Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease.

Joseph-Mathurin N, Su Y, Blazey TM, Jasielec M, Vlassenko A, Friedrichsen K, Gordon BA, Hornbeck RC, Cash L, Ances BM, Veale T, Cash DM, Brickman AM, Buckles V, Cairns NJ, Cruchaga C, Goate A, Jack CR Jr, Karch C, Klunk W, Koeppe RA, Marcus DS, Mayeux R, McDade E, Noble JM, Ringman J, Saykin AJ, Thompson PM, Xiong C, Morris JC, Bateman RJ, Benzinger TLS; Dominantly Inherited Alzheimer Network.

Alzheimers Dement (Amst). 2018 Sep 27;10:669-677. doi: 10.1016/j.dadm.2018.08.012. eCollection 2018.

43.

Depression and Alzheimer's Disease Biomarkers Predict Driving Decline.

Babulal GM, Chen S, Williams MM, Trani JF, Bakhshi P, Chao GL, Stout SH, Fagan AM, Benzinger TLS, Holtzman DM, Morris JC, Roe CM.

J Alzheimers Dis. 2018;66(3):1213-1221. doi: 10.3233/JAD-180564.

44.

Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.

Roe CM, Ances BM, Head D, Babulal GM, Stout SH, Grant EA, Hassenstab J, Xiong C, Holtzman DM, Benzinger TLS, Schindler SE, Fagan AM, Morris JC.

Brain. 2018 Nov 1;141(11):3233-3248. doi: 10.1093/brain/awy244.

45.

Widespread distribution of tauopathy in preclinical Alzheimer's disease.

Schultz SA, Gordon BA, Mishra S, Su Y, Perrin RJ, Cairns NJ, Morris JC, Ances BM, Benzinger TLS.

Neurobiol Aging. 2018 Dec;72:177-185. doi: 10.1016/j.neurobiolaging.2018.08.022. Epub 2018 Sep 1.

46.

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.

McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ; Dominantly Inherited Alzheimer Network.

Neurology. 2018 Oct 2;91(14):e1295-e1306. doi: 10.1212/WNL.0000000000006277. Epub 2018 Sep 14.

47.

Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease.

Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ.

Neurology. 2018 Aug 28;91(9):e859-e866. doi: 10.1212/WNL.0000000000006075. Epub 2018 Aug 1.

48.

Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies.

Su Y, Flores S, Hornbeck RC, Speidel B, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Xiong C, Morris JC, Benzinger TLS.

Neuroimage Clin. 2018 Apr 25;19:406-416. doi: 10.1016/j.nicl.2018.04.022. eCollection 2018.

49.

Discovery and validation of autosomal dominant Alzheimer's disease mutations.

Hsu S, Gordon BA, Hornbeck R, Norton JB, Levitch D, Louden A, Ziegemeier E, Laforce R Jr, Chhatwal J, Day GS, McDade E, Morris JC, Fagan AM, Benzinger TLS, Goate AM, Cruchaga C, Bateman RJ; Dominantly Inherited Alzheimer Network (DIAN), Karch CM.

Alzheimers Res Ther. 2018 Jul 18;10(1):67. doi: 10.1186/s13195-018-0392-9.

50.

Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease.

Lim YY, Hassenstab J, Goate A, Fagan AM, Benzinger TLS, Cruchaga C, McDade E, Chhatwal J, Levin J, Farlow MR, Graff-Radford NR, Laske C, Masters CL, Salloway S, Schofield P, Morris JC, Maruff P, Bateman RJ; Dominantly Inherited Alzheimer Network.

Ann Neurol. 2018 Sep;84(3):424-435. doi: 10.1002/ana.25299. Epub 2018 Aug 25.

Supplemental Content

Loading ...
Support Center